Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PPARG_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PPARG_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PPARG_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPARG_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PPARG_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0043467110 | Thyroid | PTC | regulation of generation of precursor metabolites and energy | 68/5968 | 130/18723 | 1.03e-06 | 1.52e-05 | 68 |
GO:000919920 | Thyroid | PTC | ribonucleoside triphosphate metabolic process | 50/5968 | 89/18723 | 1.81e-06 | 2.50e-05 | 50 |
GO:000616327 | Thyroid | PTC | purine nucleotide metabolic process | 170/5968 | 396/18723 | 2.02e-06 | 2.75e-05 | 170 |
GO:000914526 | Thyroid | PTC | purine nucleoside triphosphate biosynthetic process | 41/5968 | 69/18723 | 2.17e-06 | 2.91e-05 | 41 |
GO:000918526 | Thyroid | PTC | ribonucleoside diphosphate metabolic process | 57/5968 | 106/18723 | 2.40e-06 | 3.17e-05 | 57 |
GO:000110119 | Thyroid | PTC | response to acid chemical | 69/5968 | 135/18723 | 2.55e-06 | 3.34e-05 | 69 |
GO:000913225 | Thyroid | PTC | nucleoside diphosphate metabolic process | 64/5968 | 124/18723 | 3.80e-06 | 4.78e-05 | 64 |
GO:00063675 | Thyroid | PTC | transcription initiation from RNA polymerase II promoter | 44/5968 | 77/18723 | 4.04e-06 | 5.05e-05 | 44 |
GO:000920626 | Thyroid | PTC | purine ribonucleoside triphosphate biosynthetic process | 40/5968 | 68/18723 | 4.11e-06 | 5.11e-05 | 40 |
GO:000913526 | Thyroid | PTC | purine nucleoside diphosphate metabolic process | 55/5968 | 103/18723 | 4.75e-06 | 5.79e-05 | 55 |
GO:000917926 | Thyroid | PTC | purine ribonucleoside diphosphate metabolic process | 55/5968 | 103/18723 | 4.75e-06 | 5.79e-05 | 55 |
GO:000675325 | Thyroid | PTC | nucleoside phosphate metabolic process | 205/5968 | 497/18723 | 5.24e-06 | 6.35e-05 | 205 |
GO:000911725 | Thyroid | PTC | nucleotide metabolic process | 202/5968 | 489/18723 | 5.46e-06 | 6.60e-05 | 202 |
GO:001931810 | Thyroid | PTC | hexose metabolic process | 108/5968 | 237/18723 | 6.42e-06 | 7.65e-05 | 108 |
GO:0048511111 | Thyroid | PTC | rhythmic process | 131/5968 | 298/18723 | 7.06e-06 | 8.33e-05 | 131 |
GO:0046031110 | Thyroid | PTC | ADP metabolic process | 49/5968 | 90/18723 | 7.58e-06 | 8.77e-05 | 49 |
GO:000599614 | Thyroid | PTC | monosaccharide metabolic process | 115/5968 | 257/18723 | 9.36e-06 | 1.05e-04 | 115 |
GO:000675420 | Thyroid | PTC | ATP biosynthetic process | 34/5968 | 57/18723 | 1.41e-05 | 1.52e-04 | 34 |
GO:0007623111 | Thyroid | PTC | circadian rhythm | 96/5968 | 210/18723 | 1.74e-05 | 1.82e-04 | 96 |
GO:000914226 | Thyroid | PTC | nucleoside triphosphate biosynthetic process | 46/5968 | 85/18723 | 1.76e-05 | 1.83e-04 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPARG | SNV | Missense_Mutation | | c.724C>G | p.Leu242Val | p.L242V | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-A2-A0YC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
PPARG | SNV | Missense_Mutation | rs140204299 | c.1154N>A | p.Arg385Gln | p.R385Q | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | rs777334819 | c.235N>A | p.Glu79Lys | p.E79K | P37231 | protein_coding | tolerated_low_confidence(0.26) | benign(0.039) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
PPARG | SNV | Missense_Mutation | | c.724C>G | p.Leu242Val | p.L242V | P37231 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-OL-A66H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | novel | c.489N>G | p.Phe163Leu | p.F163L | P37231 | protein_coding | deleterious(0) | possibly_damaging(0.535) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
PPARG | insertion | Frame_Shift_Ins | novel | c.549_550insA | p.Ser186LysfsTer2 | p.S186Kfs*2 | P37231 | protein_coding | | | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PPARG | insertion | Nonsense_Mutation | novel | c.64_65insTGTTAGTAATGTAGGGATG | p.Ser22LeufsTer5 | p.S22Lfs*5 | P37231 | protein_coding | | | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPARG | SNV | Missense_Mutation | | c.181N>C | p.Asp61His | p.D61H | P37231 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.969) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PPARG | SNV | Missense_Mutation | | c.1477N>T | p.Leu493Phe | p.L493F | P37231 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-G4-6307-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD |
PPARG | deletion | Frame_Shift_Del | | c.550delN | p.Ser186ValfsTer47 | p.S186Vfs*47 | P37231 | protein_coding | | | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | GTF505 | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | BENSULIDE | BENSULIDE | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135650496 | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | SHINPTEROCARPIN | SHINPTEROCARPIN | 20022509 |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | TREPROSTINIL | TREPROSTINIL | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | modulator | CHEMBL490029 | MK-0533 | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | DICHLOROPHEN | DICHLOROPHEN | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | FLUDIOXONIL | FLUDIOXONIL | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | ETHYL EICOSAPENTAENOIC ACID | | |
5468 | PPARG | CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | AMORFRUTIN A | AMORFRUTIN A | 25938459 |